No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NGNE Neurogene
- 32.400
- -0.120-0.37%
Close May 22 16:00 ET
420.56MMarket Cap-11440P/E (TTM)
33.850High31.770Low44.84KVolume32.530Open32.520Pre Close1.46MTurnover0.75%Turnover RatioLossP/E (Static)12.98MShares53.00052wk High2.46P/B192.81MFloat Cap12.20052wk Low--Dividend TTM5.95MShs Float1115.000Historical High--Div YieldTTM6.40%Amplitude7.500Historical Low32.656Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Taysha Gene Therapies Upgraded at Jefferies on Rett Syndrome Asset
Neurogene's Strong Pipeline and Financial Health Prompt Buy Rating
Express News | Neurogene Inc : Leerink Partners Cuts Target Price to $45 From $46
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Express News | Neurogene Inc. : H.c. Wainwright Cuts Target Price to $51 From $55
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)
Comments
$Neurogene(NGNE.US$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg